The development of tyrosine kinase inhibitors (TKIs) highly specific to p210BCR-ABL1, the constitutively active tyrosine kinase encoded by BCR::ABL1, has greatly improved the prognosis for CML patients. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.